HDA Media And Political Bulletin – 8 January 2015

Chairman’s New Year Message

NPA, Ian Strachan, 5 January 2016

NPA Chairman, Ian Strachan, discusses the UK Government’s announcement of funding cuts in his New Year Welcome message. He acknowledges the concerns of the pharmacy sector and claims that the proposed plan shows little understanding of the value of the sector. The NPA accepts that technology should play an increasing role in reforming the healthcare system but should not undermine the importance of people relationship for pharmacy.

 

Scotland considers allowing pharmacists to offer flu jab

C&D, Annabelle Collins, 7 January 2016

The Scottish government is reviewing a 40-year-old law to potentially allow community pharmacy to offer vaccinations on the NHS. Community Pharmacy Scotland’s director of operations, Matt Barclay, stated that the sector has not been contacted for input yet but that the initiative was “encouraging”.

 

Drug discovery database updated with 3D data

The Pharmaceutical Journal, 6 January 2016

The publicly available drug discovery database has been updated to include 3D data. Launched by researchers at Cancer Research UK, it displays how human molecules behave in order to stimulate cancer drugs discovery.

 

Parliamentary Coverage

 

There is no Parliamentary coverage today.

 

Full Coverage

Chairman’s New Year Message

NPA, Ian Strachan, 5 January 2016

 

As we say hello to 2016, many of our thoughts go immediately to the Government’s consultation on ‘efficiencies’ that was laid out just before Christmas: a set of proposals which are high on change but low on detail and display little understanding of the real value of community pharmacy.

Many of you are angry and dismayed at the prospect of cuts to your funding. We will lobby and support the PSNC as they lead in the fight against this. But whilst I do not for one moment underestimate the difficulty such cuts will cause to independent pharmacies, I fear that the associated jumble of policy proposals is even more concerning for the long term prospects of the sector. There is no mandate for these changes and they look every bit like proposals dreamt up in Whitehall rather than developed by pharmacists at the coal face.

We must articulate to policy makers the value of our network, so that they do not think, wrongly, that large scale automation could reduce the need for bricks & mortar pharmacies, rooted in communities; that prescriptions could be collected from general convenience stores or automated collection points; that patient advice supplied through remote contact centres is equivalent to face-to-face advice given in local pharmacies by accessible health care professionals. That would be a worst-case scenario, but it is plausible to think this could be the long term outcome of the policy direction the Government is currently laying out.

The Government will never find answers for the NHS unless it asks the right questions. The NPA will start the year by asking the right questions of the Government and challenging officials’ assumptions about cost reduction.

So many of the Government’s proposals are predicated on a jumble of ideas around automation. Technology should, of course, play its role but community pharmacy is fundamentally about people; it is part of the fabric of people’s lives. In recent days we have seen the benefit of a widely distributed network of local community pharmacies:

  • Outstanding work in flood-impacted communities, including Tadcaster where an independent pharmacy is hosting GP surgeries
  • Supplying patients let down by operational failures at one of the UK’s largest existing online pharmacies

The NPA will highlight the naive thinking and consequences of scaled automation, together with the missed opportunities it would deny patient care. We will point out that medication is not some fast moving commodity and pharmacies are more than just a distribution mechanism for product. At the same time, for premises to remain viable then dispensing must remain a core activity of the network. We will also pull together and present evidence about the value of your role and propose system-wide efficiencies that can be achieved by investing in the network rather than decimating it.

Before Christmas, the NPA began to mobilise independent pharmacists to play their part in what will be a robust and coordinated response by the independent sector to the Government’s proposals. If you haven’t already done so, you can register to receive updates and ideas for how to get involved at npa.co.uk/independentsvoice. You will be given resources to build the evidence base required to make a compelling case to Government and NHS, plus hands-on support to mobilise public opinion and political support.

As we start this New Year, let me assure you we will work tirelessly to secure your future, a future in which community pharmacy can play its full role in patient care.

Ian Strachan

 

Drug discovery database updated with 3D data

The Pharmaceutical Journal, 6 January 2016

 

A drug discovery database containing billions of experimental measurements mapping the actions of drugs on human proteins has been updated to include three dimensional (3D) data.

The publically available canSAR database provides researchers with information about how human molecules behave and is thought to be the world’s largest database for cancer drug discovery. In the image, screen grab of the canSAR database

The canSAR database is thought to be the world’s largest database for cancer drug discovery.

Launched in 2011 by researchers at Cancer Research UK’s Cancer Therapeutics Unit (CTU) at the Institute of Cancer Research, the publically available canSAR database provides researchers with information about how human molecules behave and is thought to be the world’s largest database for cancer drug discovery.

In a paper published in Nucleic Acids Research[1] on 4 January 2015, CTU researchers describe enhancements to canSAR, including the 3D structures of almost 3 million cavities on the surface of nearly 110,000 protein structures.

The database provides “unique views on genes and proteins, drugs, 3D structures, protein interaction networks, cancer cell lines, cancer clinical trials and more”, write the researchers, who say the information can be used to aid target selection and prioritization for drug discovery.

“This latest research has greatly enhanced the power of canSAR to enable scientists to select the best possible targets for future cancer drug discovery and also to help them develop really innovative drugs much more rapidly and effectively than ever before,” says Paul Workman, chief executive of the Institute of Cancer Research.

The next phase of development will focus on enhancing the search and browsing options of the database, say the researchers.

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?